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Abstract
Hypothyroidism is the most common thyroid disorder, affecting about 5% of the general population.
Here we present the first large genome-wide association study of hypothyroidism, in 2,564 cases and
24,448 controls from the customer base of 23andMe, Inc., a personal genetics company. We identify four
genome-wide significant associations, two of which are well known to be involved with a large spectrum
of autoimmune diseases: rs6679677 near PTPN22 and rs3184504 in SH2B3 (p-values 3.5 · 10−13 and
3.0 · 10−11, respectively). We also report associations with rs4915077 near VAV3 (p-value 8.3 · 10−11),
another gene involved in immune function, and rs965513 near FOXE1 (p-value 3.1 · 10−14). Of these,
the association with PTPN22 confirms a recent small candidate gene study, and FOXE1 was previously
known to be associated with thyroid-stimulating hormone (TSH) levels. Although SH2B3 has been
previously linked with a number of autoimmune diseases, this is the first report of its association with
thyroid disease. The VAV3 association is novel. These results suggest heterogeneity in the genetic etiology
of hypothyroidism, implicating genes involved in both autoimmune disorders and thyroid function. Using
a genetic risk profile score based on the top association from each of the four genome-wide significant
regions in our study, the relative risk between the highest and lowest deciles of genetic risk is 2.1.
Introduction
Hypothyroidism is characterized by deficiencies of thyroid hormones T3 (triiodothyronine) and T4 (thy-
roxine). Thyroid hormones are primarily responsible for the regulation of metabolism, but also play a
major role in development. Hypothyroidism is often marked by high thyroid-stimulating hormone (TSH)
levels, which are typically indicative of impaired thyroid function; however, this is not always the case,
e.g., if reduced T3/T4 levels are caused by insufficient generation of TSH by the pituitary gland rather
than thyroid dysfunction. While iodine deficiency is the most common cause of hypothyroidism world-
wide, most cases in the developed world are due to autoimmune hypothyroidism (e.g., Hashimoto or Ord
thyroiditis). In addition, there are rare forms of congenital hypothyroidism with a number of genetic
causes [1].
The genetic determinants of TSH levels are partially understood, with several established associations
from genome-wide association studies (GWAS) [2–6]. Known associations include rs4704397 in PDE8B
(phosphodiesterase 8B) [2, 5] and rs10917469 near CAPZB (capping protein (actin filament) muscle
Z-line, beta) [4]. In a thyroid cancer GWAS, Gudmundsson et al. discovered rs965513 near FOXE1
(forkhead box E1), also known as TTF-2 (thyroid transcription factor 2) and rs944289 near NKX2-1
(NK2 homeobox 1), also known as TTF-1 (thyroid transcription factor 1) [3], and further demonstrated
an association between these two SNPs and TSH levels. A second SNP near FOXE1 (rs755109) has also
been associated with TSH levels in an isolated Pacific Island population [5]. Almost all of these regions
contain genes associated with thyroid function: in addition to the thyroid transcription factors, PDE8B
is primarily expressed in the thyroid [7] and encodes a phosphodiesterase with a high affinity for cAMP,
which mediates TSH effects in the thyroid [8].
Aside from TSH levels, Panicker et al. reported a strong association of rs2235544 in DIO1 (deiodinase,
iodothyronine, type I) with free T4/T3 ratio [9]. There have also been some studies of the genetics of
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2Hashimoto thyroiditis, the predominant cause of hypothyroidism in the United States; in particular, a
candidate gene study demonstrated an association between PTPN22 (protein tyrosine phosphatase, non-
receptor type 22 (lymphoid)) and multiple autoimmune diseases, including Hashimoto thyroiditis [10].
Earlier studies have also linked the HLA (human leukocyte antigen), CTLA4 (cytotoxic T lymphocyte
antigen 4) and the 8q23-24 regions to Hashimoto thyroiditis [11–15]. Graves’ disease (another autoimmune
thyroid disease, characterized by hyperthyroidism) has been studied in several GWAS, with many loci
discovered [16–19].
In this paper, we report on the first GWAS of hypothyroidism. We find four variants significantly
associated with hypothyroidism. Two are non-synonymous variants in genes associated with many au-
toimmune diseases (PTPN22 R620W and SH2B3 (SH2B adaptor protein 3) R262W). A third is found
in an intron of VAV3 (vav 3 guanine nucleotide exchange factor), a gene plausibly involved in immune
function. A fourth is near the thyroid transcription factor FOXE1. We also provide some support for
the genes NKX2-1, CAPZB, and PDE8B (previously associated with TSH levels) as further risk loci for
hypothyroidism.
Results
We performed a GWAS in 2,564 cases and 24,448 controls from the customer base of 23andMe, Inc.,
a personal genetics company. Briefly, participants responded to questions about their hypothyroidism
diagnosis and related thyroid issues using web-based surveys. We classified as cases individuals who
had been diagnosed with hypothyroidism, had elevated TSH levels, or were taking thyroid hormone
replacement medication. Controls reported no to at least one of the above questions and yes to none
of them. Participants reporting hyperthyroidism, thyroid cancer, thyroid removal, or treatment with
radioactive iodine for hyperthyroidism were excluded. From the set of all qualified participants, a subset
of unrelated individuals of primarily European ancestry was used in our analysis. Details about the cohort
can be found in Table 1 and the Methods. All analyses were controlled for age, sex, genotyping platform,
and five principal components. Manhattan and quantile-quantile plots are provided in Figures S1 and
S2.
Table 2 shows the genome-wide significant SNPs along with a small set of SNPs that have previously
been reported to be associated with thyroid hormone levels. The strongest association is with rs965513,
with a p-value of 3.1 · 10−14 and odds ratio (OR) of 0.78, near FOXE1 (Figure S3). This SNP has
been associated with thyroid cancer and TSH levels previously [3, 20]. Homozygous loss-of-function
mutations in this gene cause congenital hypothyroidism due to thyroid dysgenesis and other developmental
abnormalities [21].
The second association is with rs6679677, with a p-value of 3.5 · 10−13 and OR of 1.45 near PTPN22
(Figure S4). The SNP rs6679677 is in LD (r2 ≈ 0.9) with rs2476601 (the missense mutation R620W
in PTPN22, protein tyrosine phosphatase, non-receptor type 22). This mutation has previously been
associated with Hashimoto thyroiditis in a relatively small candidate gene study [10]. PTPN22 also
has well established associations with multiple autoimmune conditions [22], including type 1 diabetes,
rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis [23], Graves’ disease [24],
systemic sclerosis [25], and alopecia areata [26].
The next association, which is novel, is with rs4915077, in an intron of VAV3. This SNP has a p-value
of 8.3 · 10−11 and OR of 1.4. See Figure 1 for SNPs in this region.
The final genome-wide significant association presented in Table 2 is a novel association with rs3184504,
a missense mutation (R262W) in SH2B3, with a p-value of 3.0 · 10−10 and an OR of 0.82 (Figure S5).
This SNP has not previously been associated with thyroid disease; however, it has been associated with
a number of autoimmune diseases, including type 1 diabetes [27], celiac disease [28], rheumatoid arthi-
tis [29], and multiple sclerosis [30], as well as to hypertension and myocardial infarction [31]. The T allele
of rs3184504 is the variant associated with increased risk in our data and corresponds to the W allele in
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3the protein, which is also the risk variant in previous studies.
Table 2 also includes attempted replications of several other SNPs previously associated with TSH
levels. In the NKX2-1 region, we find only suggestive evidence for the SNP reported in [3] (rs944289,
with a p-value of 0.096); however, a nearby SNP (rs378836) shows a stronger signal (p-value of 3.2 ·10−5).
These SNPs are in partial LD (r2 = 0.3), suggesting that they may represent the same signal (Figure S6).
Near CAPZB, the SNP that was originally reported, rs10917469, was not present on our genotyping
platforms, but we did genotype rs10799824, which is in LD (r2 = 1) with rs10917469. rs10799824 shows
only suggestive evidence here (p-value of 0.066), but a second SNP in this region, rs1472565 (which is not
in LD with rs10799824 and rs10917469) does show a signal, with a p-value of 7.9 · 10−6, Figure S7. We
replicated the association with rs4704397 near PDE8B at a modest level of significance (p-value of 0.021)
and failed to replicate both the second association found near FOXE1 in a non-European population,
rs755109 (p-value of 0.73) (see Figure S8) and rs2235544 in DIO1 (p-value of 0.76).
All SNPs with p-values under 10−4 are shown in Table S1. The most notable of these 131 suggestive
SNPs is perhaps rs9277535 in the HLA region, with a p-value of 4 · 10−5. The HLA has been associated
with many autoimmune conditions (cf. [32]).
Discussion
We have presented two novel associations with hypothyroidism: the non-synonymous change R262W in
SH2B3, and the SNP rs4915077 near VAV3. SH2B3 has been associated with a host of autoimmune
diseases and thus is a good candidate for hypothyroidism. VAV3 has not yet been associated with
autoimmune disease or thyroid function. However, it has been proposed as the candidate gene in the
Idd18.1 region linked with type 1 diabetes in mouse [33], and the Vav1/Vav2/Vav3 family is necessary for
adaptive immune function in mouse [34]. VAV3 is also expressed in the thyroid [35] and is down-regulated
in a subset of thyroid tumors [36].
We have found one more association with a mutation well known to be involved in autoimmune
disease: R620W in PTPN22. This association has been observed before in a small candidate gene study
of Hashimoto thyroiditis [10]. That study found, in a sample of 194 cases and 2064 controls, an OR
of 1.77 (1.31–2.40) for rs2476601/R620W. We observe an OR for this SNP of 1.42 (1.29–1.57), which is
within their confidence interval, despite slightly different phenotypes.
While many autoimmune diseases share genetic risk factors in common [32], there is evidence that
these diseases form separate clusters based on genetics [37]. For example, the 620W allele of PTPN22
has a protective effect in Crohn’s disease [38] but is the risk allele for type 1 diabetes and others [39].
The associations with SH2B3 and the 620W allele of PTPN22 thus suggest that hypothyroidism falls
into the same cluster as type 1 diabetes, for example.
We have also attempted to replicate several SNPs associated with thyroid hormone levels. The only
one that replicated strongly was the association between thyroid cancer and TSH levels with the thyroid
transcription factor FOXE1 [3]. We find suggestive (but not genome-wide significant) evidence for the
genes NKX2-1, CAPZB and PDE8B previously reported in TSH studies. This suggests that while
autoimmune loci may play a predominant role in the genetics of hypothyroidism, there may be smaller
effects due to genes more directly related to thyroid function and hormone levels.
Due to the nature of online self-report, we have not gathered clinical measures such as TSH levels or
hypothyroidism symptoms. Hypothyroidism is thought to be generally under-diagnosed (but could even
be over-diagnosed in a health-conscious group of participants), thus there could be some misclassification
among participants. About 7.5% of females and 2.8% of males are estimated to have elevated TSH
levels and 2-3% of people are estimated to have overt symptoms of hypothyroidism [40]. This is roughly
in the same range as the 9.5% prevalence of hypothyroidism (defined as either elevated TSH levels or
hypothyroidism diagnosis) in our cohort. In addition, given the replication of loci associated with TSH,
this misclassification does not appear to be a large problem here. Ultimately, the loci discovered here
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4should be further evaluated in a more deeply phenotyped hypothyroidism population, to determine the
interplay between thyroid function genes and immune system genes that leads to this disorder.
Methods
Cohort
All participants in the study were customers of 23andMe, Inc., a personal genetics company, who had been
genotyped as part of the 23andMe Personal Genome Service R©. Individuals included in the cohort were
selected for being of primarily European ancestry, as determined through an analysis of local ancestry
via comparison to the three HapMap 2 populations, using an unpublished method substantially similar
to [41]. This subset was selected as it is the largest relatively unstructured set within the 23andMe
customer base.
A maximal set of unrelated individuals was chosen for the analysis using a segmental identity-by-
descent (IBD) estimation algorithm (as used in [42]). Individuals were defined as related if they shared
more than 700 cM IBD, including both regions where the two individuals share either one or both
genomic segments identical-by-descent. This level of relatedness (roughly 20% of the genome) corresponds
approximately to the minimal expected sharing between first-cousins in an outbred population.
This study was conducted according to the principles expressed in the Declaration of Helsinki. The
study protocol and consent form were approved by the external AAHRPP-accredited IRB, Ethical and
Independent Review Services (E&I Review). Our consent and privacy statement preclude the sharing of
individual-level data without explicit consent. We have, however, shared summary statistics for all SNPs
with p-values under 10−4 in Table S1.
Genotyping
For the 23andMe cohort, DNA extraction and genotyping were performed on saliva samples by National
Genetics Institute (NGI), a CLIA-certified clinical laboratory and subsidiary of Laboratory Corporation
of America. Samples were genotyped on one of three different platforms. About 70% of the participants
were genotyped on one of two platforms based on the Illumina HumanHap550+ BeadChip (called V1 and
V2 in Table 1), which included SNPs from the standard HumanHap550 panel augmented with a custom set
of approximately 25,000 SNPs selected by 23andMe. Two slightly different versions of this platform were
used, as described in [42]. The remaining participants were genotyped on the Illumina OmniExpress+
Bead Chip. This platform has a base set of 730,000 SNPs. It was augmented by approximately 250,000
SNPs to make it approximately a superset of the HumanHap550+, as well as a custom set of about
30,000 SNPs. This platform was called V3 in Table 1. Every sample that failed to reach a 98.5% call
rate for SNPs on the standard platforms was re-analyzed. Individuals whose analyses failed repeatedly
were re-contacted by 23andMe customer service to provide additional samples, as is done for all 23andMe
customers. See [42] for further details on the genotyping and sample quality controls.
SNPs with a call rate under 95% or minor allele frequency under 0.01 were excluded from analysis.
Call rates were calculated on a per-platform basis. Additionally, SNPs with Hardy-Weinberg p-values [43]
less than than 10−20 were excluded. Altogether, 870,065 SNPs (on the union of the two platforms) were
retained with an average call rate of 99.78%.
Phenotyping
Participants were able to fill out web-based questionnaires whenever they logged into their 23andMe
accounts. Participants answered some of the following questions:
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5• Have you ever been diagnosed by a doctor with any of the following thyroid conditions? (asked as
part of a medical history questionnaire)
– Hyperthyroidism
– Hypothyroidism
• Have you been diagnosed with any of the following? (asked as part of a questionnaire on baldness)
– Hyperthyroidism (overactive thyroid)
– Hypothyroidism (underactive thyroid)
• Have you ever been diagnosed with hypothyroidism (underactive thyroid)?
• Do you currently take medication for hypothyroidism (low thyroid hormone levels)?
• Have you ever been told by a doctor that your thyroid stimulating hormone (TSH) levels were
elevated, indicating hypothyroidism?
• Have you ever been diagnosed with thyroid cancer?
• Have you ever received radioactive iodine treatment for goiter or hyperthyroidism (overactive thy-
roid)?
• Have you ever had all or part of your thyroid surgically removed?
• Have you ever been diagnosed by a doctor with any of the following common cancers? (asked as
part of a medical history questionnaire)
– Thyroid cancer
Cases answered yes to hypothyroidism or to elevated TSH levels or to taking medication for hypothy-
roidism. Controls answered no to at least one of the qualifying questions and yes to none of them.
Individuals reporting hyperthyroidism or thyroid cancer or treatment with radioactive iodine or thyroid
removal were excluded, as all of these could cause hypothyroidism or could signal Graves’ disease.
As customers of 23andMe, all participants had the opportunity to view reports based on their genetic
information on over 100 traits and diseases. Among these diseases were reports on thyroid cancer (covering
the FOXE1 and NKX2-1 SNPs from [3]) and Hashimoto thyroiditis (covering PTPN22 ). It is unlikely
that a predicted high or low risk for thyroid cancer would lead to misreport of hypothyroidism. For
PTPN22, there was no evidence of a difference in ORs for rs2476601 and hypothyroidism for people
viewing their results before or after answering survey questions (p = 0.89 for interaction).
Statistical analysis
For the association analysis, all p-values were calculated using a likelihood ratio test for the logistic
regression model, adjusting for sex, age, genotyping platform, and projections onto the first five principal
components of the genotype data matrix. The phenotypic status of each individual was coded as 0 for
unaffected individuals and 1 for affected individuals. Genotypes were coded 0, 1, or 2, to indicate the
number of minor alleles present for the tested SNP (corresponding to a log-additive model of association).
Reported odds ratios for each SNP relative to the minor allele were defined as the exponential of the
regression coefficients, and the alleles used throughout refer to the plus strand of NCBI build 36.3 of
the human genome. We used a cutoff for genome-wide significance of 5 · 10−8 (corresponding to a
Bonferroni correction assuming 1 million independent tests). We did not attempt to formalize a criterion
for replication of previously associated SNPs, as previous GWAS have tested different aspects of thyroid
function from the broad definition of hypothyroidism used here.
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Figure 1. SNPs in the VAV3 region. In the plot, circles represent unannotated SNPs, upside-down
triangles represent non-synonymous variants, and boxes with an “x” are SNPs in regions that are highly
conserved across 44 placental mammals. Colors depict the squared correlation (r2) of each SNP with
the most associated SNP (i.e., rs4915077, shown in purple). Gray indicates SNPs for which r2
information was missing. Plots were produced using the LocusZoom program [44].
Figure S1. Manhattan plot. Negative log p-values for SNPs by genome position. Genome-wide
significant SNPs are shown in red.
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Figure S2. Quantile-quantile plot. Observed p-values versus theoretical p-values under the null
hypothesis of no association. The genomic control inflation factor for the study was 0.98 and is
indicated by the red line.
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Figure S3. SNPs in the FOXE1 region. For details, see Figure 1.
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Figure S4. SNPs in the PTPN22 region. For details, see Figure 1.
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Figure S5. SNPs in the SH2B3 region. For details, see Figure 1.
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Figure S6. SNPs in the NKX2-1 region. For details, see Figure 1.
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Figure S7. SNPs in the CAPZB region. For details, see Figure 1.
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Figure S8. SNPs in the PDE8B region. For details, see Figure 1.
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Tables
Table 1. Cohort statistics
Number Female Male
Control 24448 8917 (36.5%) 15531 (63.5%)
Case 2564 1891 (73.8%) 673 (26.2%)
< 45 46–55 56–65 > 65
Control 11850 (48.5%) 3903 (16.0%) 4673 (19.1%) 4022 (16.5%)
Case 580 (22.6%) 419 (16.3%) 801 (31.2%) 764 (29.8%)
V1 V2 V3
Control 260 (1.1%) 16482 (67.4%) 7706 (31.5%)
Case 27 (1.1%) 1845 (72.0%) 692 (27.0%)
Participants broken down by sex, age, and genotyping platform. V1, V2, and V3 refer to the three
platforms used in this study, see Methods.
Table 2. Statistics for genome-wide significant SNPs and selected replications.
SNP Chr. Pos. Region Alleles MAF HWE p-value OR
rs965513 9 99595930 FOXE1 G/A 0.331 0.23 3.1 · 10−14 0.778 (0.73 - 0.83)
rs6679677 1 114105331 PTPN22 C/A 0.090 0.74 3.5 · 10−13 1.445 (1.31 - 1.59)
rs2476601 1 114179091 PTPN22 G/A 0.091 0.66 4.6 · 10−13 1.439 (1.31 - 1.58)
rs4915077 1 108167539 VAV3 T/C 0.084 0.32 8.3 · 10−11 1.397 (1.27 - 1.54)
rs3184504 12 110368991 SH2B3 T/C 0.499 0.31 3 · 10−10 0.823 (0.77 - 0.87)
rs378836 14 35561627 NKX2-1 G/A 0.432 0.96 3.2 · 10−5 1.137 (1.07 - 1.21)
rs944289 14 35718997 NKX2-1 T/C 0.427 0.61 0.096 1.053 (0.99 - 1.12)
rs1472565 1 19627617 CAPZB T/C 0.476 0.78 7.9 · 10−6 1.147 (1.08 - 1.22)
rs10799824 1 19713761 CAPZB G/A 0.153 0.31 0.066 0.853 (0.72 - 1.01)
rs4704397 5 76554198 PDE8B G/A 0.388 0.5 0.021 1.152 (1.02 - 1.30)
rs755109 9 99736024 FOXE1 T/C 0.367 0.11 0.73 0.976 (0.86 - 1.10)
rs2235544 1 54148158 DIO1 A/C 0.496 0.16 0.76 0.991 (0.93 - 1.05)
All genomic positions are given with respect to NCBI build 36.3. Alleles are listed as major/minor and
are specified for the forward strand. Odds ratios are per copy of the minor allele. Two SNPs are listed
for PTPN22 ; of these, rs2476601 is the non-synonymous change R620W.
Table S1. SNPs with p-values under 10−4
See Table 2 for details on columns.
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